Loading...
XSWX
BANB
Market cap6.24bUSD
Jun 18, Last price  
67.00CHF
1D
-0.15%
1Q
8.33%
Jan 2017
-25.80%
IPO
-36.34%
Name

Bachem Holding AG

Chart & Performance

D1W1MN
XSWX:BANB chart
P/E
41.75
P/S
8.30
EPS
1.60
Div Yield, %
1.27%
Shrs. gr., 5y
1.62%
Rev. gr., 5y
14.05%
Revenues
605m
+4.84%
153,656,000171,754,000198,318,000194,997,000181,848,000152,884,000145,808,000157,298,000170,685,000183,937,000208,604,000236,478,000261,612,000282,500,000313,715,000401,995,000503,234,000531,741,000577,316,000605,259,000
Net income
120m
+7.50%
39,232,00046,649,00063,927,00058,709,00046,057,00028,297,0009,409,00015,300,00023,604,00029,065,00031,838,00041,205,00041,770,00046,644,00054,164,00078,062,000114,682,000100,684,000111,859,000120,248,000
CFO
146m
-41.44%
27,423,00040,150,00078,070,00039,277,00042,847,00038,110,00024,609,00036,871,00049,230,00047,218,00061,434,00040,409,00036,479,00025,776,00063,648,000114,628,00097,163,00092,589,000249,864,000146,322,000
Dividend
May 05, 20250.85 CHF/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Bachem Holding AG is a global partner to pharmaceutical and biotechnology companies, supplying crucial products and services for every stage from early-stage research and clinical trials to full-scale commercialization. The company specializes in the creation, manufacturing, and regulatory assistance for peptide active pharmaceutical ingredients (APIs), particularly novel peptide and oligonucleotide chemical entities (NCEs). Beyond these, Bachem also offers established commercial NCEs and generic medications. Its comprehensive service offerings include project oversight, quality assurance, regulatory compliance guidance, advanced analytical testing, GMP-compliant production, specialized research-grade manufacturing, and integrated supply chain solutions. The company, established in 1971, operates from its headquarters in Bubendorf, Switzerland.
URL
https://www.bachem.com/
IPO date
Jun 29, 2001
Employees
1,926
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT